2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of Health
2019
Chapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.Chapters
2018
The present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2013
Reliable Assessment of Insulin Resistance in Children
Van Name M, Caprio S. Reliable Assessment of Insulin Resistance in Children. Current Cardiovascular Risk Reports 2013, 7: 256-260. PMID: 36845034, PMCID: PMC9957558, DOI: 10.1007/s12170-013-0315-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements